Singapore’s pioneering biotech firm, Mirxes, has teamed up with Oracle to deploy an AI-enabled clinical support system aimed at expediting cancer diagnostics. Announced at the Oracle AI World Tour in Singapore, the collaboration has resulted in an AI assistant designed to provide clinicians with rapid, accurate responses to complex medical enquiries, thereby improving patient outcomes.
Mirxes, recognised as Singapore’s first biotech unicorn in 2025, is leveraging Oracle’s AI Database and Cloud Infrastructure to meet the growing demand for its microRNA-based cancer detection solutions. The AI assistant, developed with the Oracle AI Customer Excellence Centre, is grounded in curated medical literature and product documentation, ensuring clinicians receive precise information swiftly. This innovation is set to streamline the delivery of clinical knowledge, allowing healthcare professionals to focus more on direct patient care.
Dr Zhou Lihan, co-founder and CEO of Mirxes, emphasised the importance of precision and speed in early cancer detection. “By providing clinicians with fast access to accurate, up-to-date information, we can reduce their burden and allow them to focus on patient care,” he stated.
The AI assistant uses advanced technologies like semantic search and retrieval-augmented generation to interpret clinician queries and deliver contextually relevant answers. This initiative not only enhances clinician efficiency but also supports Mirxes’ global expansion efforts, ensuring consistent knowledge delivery across regions.
Chin Ying Loong, Oracle’s senior vice president, highlighted the collaboration’s potential to scale trusted clinical knowledge delivery and improve patient outcomes. As Mirxes continues to innovate, this partnership marks a significant step in advancing cancer early detection solutions globally.
